Splenomegaly patterns and clinical impact in African children with sickle cell anemia on hydroxyurea treatment
Notice bibliographique
Résumé
Abstract Introduction. Splenomegaly is a challenging complication for children with sickle cell anemia (SCA) in sub-Saharan Africa, with little experience gained from high-income countries where splenic infarction and involution occur early in life. The etiology, persistence, and consequences of splenomegaly are poorly understood, especially regarding the effects of hydroxyurea treatment. Realizing Effectiveness Across Continents with Hydroxyurea (REACH, NCT01966731 and NCT06171217) is an ongoing Phase 1/2 trial of open-label hydroxyurea with dose optimization to maximum tolerated dose (MTD) for children with SCA in four African countries. With over 5,000 participant-years of treatment exposure, we address the characteristics and consequences of splenomegaly in this clinical setting. Methods. Children aged 1-10 years with SCA were enrolled at 4 clinical sites in Angola, Democratic Republic of Congo, Kenya, and Uganda. After a 3-month screening phase, hydroxyurea was prescribed at fixed dose for 6 months, escalated to MTD by Month 24, and subsequently optimized with mild myelosuppression. Spleen size below the costal margin was recorded at each scheduled and unscheduled visit. Cross-sectional analysis compared age, sex, clinical site, growth parameters, alpha thalassemia (1-gene or 2-gene deletion), and G6PD deficiency across four baseline spleen categories: non-palpable, moderate (1-4 cm), large (≥ 5 cm), or splenectomy with correlations. Longitudinal analysis categorized the frequency of palpable splenomegaly over repeated assessments as never (splenectomy), rare (<5%), intermittent (5-50%), or persistent (>50%). Mean laboratory values and current optimized daily doses were calculated in these categories, plus rates per 100 patient-years (pt-yr) for dose-limiting toxicities (DLT), transfusions, malaria infections, and deaths. Rate ratios (RR) and 95% confidence intervals were calculated for persistent vs. non-persistent splenomegaly. Results: A total of 606 children started hydroxyurea. At enrollment, 10/606 (1.7%) had splenectomy, 49/606 (8.1%) had moderate splenomegaly, and 50/606 (8.3%) had large splenomegaly. Compared to no palpable spleen, any splenomegaly at baseline was associated with a lower hemoglobin (6.9±1.3 vs 7.3±1.0 g/dL, p<0.001) and lower platelet count (287±117 vs 432±168 x 109/L, p<0.001). Children with alpha thalassemia had a greater prevalence of baseline splenomegaly (20.0% vs 12.4%, p=0.0019), but G6PD deficiency had no effect. Excluding 10 children with splenectomy at enrollment, palpable splenomegaly was recorded at least once during treatment in 346/596 (58.1%) children, usually in the first 2 years. Children with 2-gene deletion alpha thalassemia also had a higher risk of developing splenomegaly (~70% vs. ~50%, p=0.004). Over 8.5±2.4 years of follow-up and a median of 54 assessments per child, palpable splenomegaly was rare in 384/596 (64.4%), intermittent in 148/596 (24.8%), and persistent in 64/596 (10.7%). The average optimized hydroxyurea doses for these 3 categories were 28.6±5.3 mg/kg/day, 27.1±6.1 mg/kg/day, and 23.1±6.4 mg/kg/day, p<0.001. Lab consequences of persistent splenomegaly, compared to rare or intermittent splenomegaly, included a lower hemoglobin (6.9±1.4 vs 8.2±1.3 g/dL, p<0.001), lower MCV (90±12 vs 97± 14 fL, p<0.001), and lower platelet count (201±83 vs 383±171 x 109/L, p<0.001), but a slighter higher absolute neutrophil count (4.3±2.1 vs 3.9±1.8 x 109/L, p=0.122). Additional consequences of persistent splenomegaly included a high rate of DLT (67.0/100 pt-yr; RR=3.72 [2.62-5.37]; p<0.001), particularly for anemia and thrombocytopenia. Transfusions (31.0/100 pt-yr; RR=4.54 [3.08-6.78]; p<0.001) and all-cause death (2.3/100 pt-yr, RR=2.38 [1.15-4.55]; p=0.028) were also more common. Malaria was highest in children with intermittent splenomegaly (31.6/100 pt-yr; RR=1.58 [1.27-1.96]; p<0.001). Conclusions. Splenomegaly is common among children with SCA living in sub-Saharan Africa and complicates their clinical care despite sustained hydroxyurea at MTD. Persistent splenomegaly is especially problematic and associated with lower baseline lab values, lower hydroxyurea doses, more DLT, and greater clinical morbidity including more transfusions and more deaths. The importance of alpha thalassemia and recurrent malaria in the development of splenomegaly remains poorly understood. New recommendations for wider malaria chemoprophylaxis may help reduce splenomegaly in children with SCA.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,002 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,001 | 0,000 |
| Communication savante | 0,001 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».